Serum Collagen Triple Helix Repeat Containing-1 Levels are Related to Radiological Affection and Disease Activity in Rheumatoid Arthritis

Figures & data

Table 1 Relation Between Clinical and Laboratory Findings and Disease Activity

	All Patients N=60	Disease Activity		p value
		Remission-to-Moderate n=31	High n=29
Age (years) median (IQR)	47.0 (42.0–62.0)	46.0 (40.0–59.0)	59.0 (42.0–67.0)	0.27
Male/female n	2/58	2/29	0/29	0.16
Disease duration (years) median (IQR)	12.5 (8.0–18.0)	14.0 (9.0–25.0)	10.0 (8.0–15.0)	0.19
Clinical findings n (%)
Extra-articular manifestations n (%)	34 (56.7)	20 (64.5)	14 (48.3)	0.21
Tender joints median (IQR)	12.0 (8.0–14.0)	8.0 (4.0–10.0)	14.0 (12.0–17.0)	<0.001
Swollen joints median (IQR)	4.0 (2.0–6.0)	2.0 (2.0–5.0)	6.0 (3.5–7.0)	<0.001
mHAQ median (IQR)	1.19 (0.88–1.63)	0.88 (0.75–1.0)	1.5 (1.38–1.88)	<0.001
Laboratory data median (IQR)
Hb (gm/dL)	10.8 (9.9–11.2)	10.8 (9.9–11.2)	10.8 (9.8–11.6)	0.97
WBCs (×10^3/mL)	7.6 (5.6–8.9)	7.4 (6.2–8.5)	7.7 (5.1–9.6)	0.66
Platelets (×10^3/mL)	262.0 (192.0–302.0)	280.0 (210.0–301.0)	245.0 (189.0–312.0)	0.53
ESR mm/hr	30.0 (15.0–50.0)	30.0 (20.0–50.0)	30.0 (15.0–40.0)	0.58
CRP (mg/dL)	12.0 (7.0–20.0)	10.0 (6.0–24.0)	12.0 (7.3–20.0)	0.48
RF (IU/mL)	17.2 (10.4–28.6)	13.2 (10.4–31.2)	17.9 (11.6–28.6)	0.4
Anti-CCP (U/mL)	112.5 (79.0–369.0)	120.0 (89.2–297.2)	110.0 (78.7–408.0)	0.78
CTHRC1 (mg/dL)	4.66 (1.68–11.7)	2.23 (1.4–4.73)	6.55 (4.66–12.0)	0.004
Simple Erosion Narrowing Score (SENS) median (IQR)
Erosion score	3.0 (1.0–5.0)	2.0 (1.0–3.0)	4.0 (2.5–9.5)	<0.001
Narrowing score	4.5 (3.0–7.0)	3.0 (2.0–5.0)	7.0 (4.0–11.0)	<0.001
Total score	7.0 (4.0–11.8)	6.0 (3.0–8.0)	11.0 (6.0–20.5)	<0.001

Abbreviations: Anti-CCP, anti-cyclic citrullinated peptide; CRP, C-reactive protein; CTHRC1, collagen triple helix repeat containing 1; ESR, Erythrocyte Sedimentation Rate; Hb, hemoglobin; mHAQ, modified Health Assessment Questionnaire; RF, rheumatoid Factor; WBCs, white blood cells.

Figure 1 CTHRC1 in the studied groups.

Table 2 Relation Between Clinical and Laboratory Findings and Radiological Damage

	Simple Erosion Narrowing Score		p value
	< Median n=26	≥ Median n=34
Age (years) median (IQR)	45.0 (40.0–64.0)	53.0 (42.0–61.3)	0.25
Male/female n	25/1	33/1	0.85
Disease duration (years) median (IQR)	12.5 (8.8–25.0)	12.5 (7.8–15.8)	0.52
Clinical findings
Extra-articular manifestations n (%)	15 (57.7)	19 (55.9)	0.89
Tender joints median (IQR)	8.0 (3.8–12.0)	13.0 (10.0–16.0)	0.001
Swollen joints median (IQR)	2.0 (1.8–5.0)	4.5 (3.0–7.0)	0.002
mHAQ median (IQR)	1.0 (0.75–1.25)	1.38 (1.0–1.66)	0.006
Laboratory data median (IQR)
Hb (gm/dL)	10.8 (10.0–11.3)	10.8 (9.8–11.2)	0.53
WBCs (×10^3/mL)	7.7 (6.1–9.1)	7.6 (5.3–8.7)	0.4
Platelets (×10^3/mL)	237.5 (204.8–300.0)	278.0 (192.0–317.0)	0.38
ESR mm/hr	29.0 (20.0–46.3)	32.5 (15.0–50.0)	0.96
CRP (mg/dL)	9.0 (6.0–18.0)	12.0 (7.4–24.0)	0.14
RF (IU/mL)	24.0 (9.7–39.5)	15.1 (10.4–22.1)	0.26
Anti-CCP (U/mL)	112.5 (78.5–405.0)	115.0 (79.8–369.0)	0.7
CTHRC1 (mg/dL)	1.99 (1.4–4.66)	9.75 (4.39–12.63)	<0.001
DAS28 median (IQR)	4.25 (2.9–5.2)	5.4 (4.65–5.8)	0.01
Disease activity n (%)
Remission	4 (15.4)	3 (8.8)	0.12
Low	5 (19.2)	3 (8.8)
Moderate	9 (34.6)	7 (20.6)
High	8 (30.8)	21 (61.8)

Table 3 Correlation Between CTHRC1 Levels and Clinical and Laboratory Data in RA Patients

	CTHRC1
	r	p
Age	0.25	0.056
Disease duration	0.24	0.064
Tender joints	0.33	0.01
Swollen joints	0.19	0.14
mHAQ	0.47	<0.001
Hb	0.17	0.21
WBCs	−0.05	0.7
Platelets	−0.15	0.26
ESR	−0.071	0.59
CRP	−0.17	0.2
RF	−0.053	0.69
Anti-CCP	0.11	0.4
DAS28	0.42	<0.001
Erosion score	0.57	<0.001
Narrowing score	0.62	<0.001
Total SENS	0.62	<0.001

Figure 2 Correlation between CTHRC1 and DAS28.

Figure 3 Correlation between CTHRC1 and total SENS.